Hemogenyx Pharmaceuticals Plc

HEMO.L · LSE
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-£5,004-£2,806-£3-£2,370
Dep. & Amort.£314£318£0£326
Deferred Tax£0£0£0£634
Stock-Based Comp.£0£0£0£0
Change in WC£583£569£67-£793
Other Non-Cash£324£136-£2,415-£488
Operating Cash Flow-£3,783-£1,783-£2-£2,775
Investing Activities
PP&E Inv.-£4-£13£0-£104
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.£264-£12£17£0
Investing Cash Flow£260-£25£17-£104
Financing Activities
Debt Repay.-£346£0-£318£0
Stock Issued£2,018£552£3,160£1,170
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.£0-£317£0-£321
Financing Cash Flow£1,672£235£2,843£849
Forex Effect£1,919£90-£114£107
Net Chg. in Cash£67-£1,483£395-£1,837
Supplemental Information
Beg. Cash£159£1,643£1,248£2,533
End Cash£227£159£1,643£1,248
Free Cash Flow-£3,787-£1,797-£2-£2,879
Hemogenyx Pharmaceuticals Plc (HEMO.L) Financial Statements & Key Stats | AlphaPilot